Key result
Kv7 channel openers show therapeutic potential for diseases driven by dopaminergic and serotonergic overactivity.
Why the study?
The influence of neuronal Kv7 channels on dopaminergic and serotonergic neurotransmission and their therapeutic potential in related diseases is not fully understood.
Answers are grounded in this paper and cite their sources.
Kv7 channel openers represent a potential novel therapeutic approach for conditions involving dopaminergic or serotonergic overactivity, such as schizophrenia, drug abuse, and anxiety.
Neuronal Kv7 channels (also termed KCNQ channels) are the molecular correlate of the M-current. The Kv7 channels activate at rather negative membrane potentials (< or = 60 mV), thereby 'fine-tuning' the resting membrane potential. The Kv7 channels are widely expressed in the brain with the Kv7.2, Kv7.3 and Kv7.5 channels being the most abundant. The Kv7.4 subunit has the most restricted brain regional expression being present in discrete nuclei of brainstem only. Kv7 channels are expressed at different subcellular locations, being on both somatodendritic, axonal and terminal sites. This complex subcellular distribution of Kv7 channels enables them to participate in both pre- and postsynaptic modulation of basal and stimulated excitatory neurotransmission. Activation of neuronal Kv7 channels limits repetitive firing thereby potentially limiting the generation of long bursts, with subsequent inhibition of monoaminergic neurotransmitter release. In this review, we focus on the influence of Kv7 channels on dopaminergic and serotonergic neurotransmission. The data suggest a novel action of Kv7 channel openers which could translate into having therapeutic value in the treatment of disease states characterized by overactivity of dopaminergic (e.g. schizophrenia and drug abuse) and serotonergic neurotransmission (e.g. anxiety).
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2008) conducted a review in Overactivity of dopaminergic and serotonergic neurotransmission (e.g., schizophrenia, drug abuse, anxiety). Kv7 channel openers was evaluated. Kv7 channel openers may have therapeutic value in treating disease states characterized by overactivity of dopaminergic and serotonergic neurotransmission, such as schizophrenia, drug abuse, and anxiety.
Synapse has enriched 10 related papers. Consider them for comparative context: